Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools.
The recent identification of key molecular protagonists involved in osteoclast biology has led to the development of new therapeutic approaches of osteolytic diseases using biological molecules which could compete with bisphosphonate therapy.
Heymann
Dominique
D
Pathophysiology of Bone Resorption Laboratory and Therapy of Primitive Bone Tumors, EA3822, INSERM ERI 7, Medicine Faculty, 1 rue Gaston Veil, 44035 Nantes cedex 1, France. dominique.heymann@univ-nantes.fr
Fortun
Yannick
Y
Rédini
Francoise
F
Padrines
Marc
M
D000818:Animals; D004164:Diphosphonates / Q000627:therapeutic use; D015195:Drug Design; D006023:Glycoproteins / Q000627:therapeutic use; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors; D018716:Molecular Mimicry; D010014:Osteolysis / Q000188:drug therapy*; D053244:Osteoprotegerin; D010455:Peptides / Q000737:chemistry; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
D004164:Diphosphonates; D006023:Glycoproteins; D039302:Integrin alphaVbeta3; D053244:Osteoprotegerin; D010455:Peptides; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; C506030:TNFRSF11B protein, human